Metformin ER

Clinical trial examining the effect of metformin combined with a low-calorie diet on metabolic outcomes in obese and overweight adults with increased waist circumference.

Phase III randomized controlled trial evaluating extended-release metformin's ability to normalize glycosylated hemoglobin in breast cancer survivors with insulin resistance. Study also investigates metformin's effects on epigenetic changes and inflammatory cytokines.

Comprehensive review demonstrating that metformin reduces cardiovascular events by 39% in type 2 diabetes patients and provides sustained 33% reduction in myocardial infarction risk over 10 years. Study also documents metformin's effects on inflammation and potential anticancer mechanisms.

Large rigorous clinical trial demonstrating that metformin reduced emergency room visits, hospitalization, or death from COVID-19 by 42%, with over 50% reduction in serious outcomes when taken immediately after symptom onset.

Phase III randomized controlled trial evaluating extended-release metformin's ability to normalize glycosylated hemoglobin in breast cancer survivors with insulin resistance. Study also investigates metformin's effects on epigenetic changes and inflammatory cytokines.

Clinical trial examining the effect of metformin combined with a low-calorie diet on metabolic outcomes in obese and overweight adults with increased waist circumference.

Phase III randomized controlled trial evaluating extended-release metformin's ability to normalize glycosylated hemoglobin in breast cancer survivors with insulin resistance. Study also investigates metformin's effects on epigenetic changes and inflammatory cytokines.

Study of 304 diabetic patients with chronic heart failure showed that 3 months of metformin treatment (1000 mg twice daily) significantly reduced myocardial oxygen uptake by 17%, with better myocardial efficiency in patients with higher plasma metformin concentrations.

Comprehensive review demonstrating that metformin reduces cardiovascular events by 39% in type 2 diabetes patients and provides sustained 33% reduction in myocardial infarction risk over 10 years. Study also documents metformin's effects on inflammation and potential anticancer mechanisms.

Comprehensive review demonstrating that metformin reduces cardiovascular events by 39% in type 2 diabetes patients and provides sustained 33% reduction in myocardial infarction risk over 10 years. Study also documents metformin's effects on inflammation and potential anticancer mechanisms.